SCHEMBL13340286

SCHEMBL13340286

C[C@H](Nc1cncc(-c2ccc(N3CCN(C)CC3)nc2)n1)c1cccc(NC(=O)c2cccc(C(F)(F)F)c2)c1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CSF1R P07333 13/20 0.63
BRAF P15056 3/20 0.57
RAF1 P04049 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.49
GSK3B P49841 1/20 0.48
DYRK1A Q13627 1/20 0.48
SRC P12931 2/20 0.48
KDR P35968 2/20 0.48
RET P07949 1/20 0.48
PDGFRB P09619 1/20 0.48
KIT P10721 1/20 0.48
PDGFRA P16234 1/20 0.48
FLT1 P17948 1/20 0.48
FLT4 P35916 1/20 0.48
FRK P42685 1/20 0.48
DDR1 Q08345 1/20 0.48
KDM4E B2RXH2 1/20 0.47
MAPT P10636 1/20 0.47
ABL1 P00519 1/20 0.45
LCK P06239 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13340395 0.92 CSF1R (0.62) CSF1RBRAFRAF1
SCHEMBL13340272 0.91 CSF1R (0.65) CSF1RBRAFRAF1SMN1; SMN2SRC
SCHEMBL19447128 0.90 CSF1R (0.61) CSF1RGSK3BDYRK1ASRCKDR
SCHEMBL13340085 0.90 CSF1R (0.61) CSF1RGSK3BDYRK1ASRCKDR
SCHEMBL13340409 0.86 CSF1R (0.65) CSF1RBRAFSRCKDRRET
SCHEMBL19447232 0.86 CSF1R (0.65) CSF1RBRAFSRCKDRRET
SCHEMBL17954640 0.83 CSF1R (0.73) CSF1RSRCKDRRETPDGFRB
SCHEMBL19447287 0.82 LDHA (0.45) CSF1RGSK3BDYRK1AFYN
SCHEMBL3475138 0.82 CSF1R (0.71) CSF1RSRCKDRRETPDGFRB
SCHEMBL13340382 0.82 CSF1R (0.71) CSF1RSRCKDRRETPDGFRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2848610-B1 Inhibitors of kinase activity YM BIOSCIENCES AUSTRALIA PTY (AU) 2017-10-11 EP disclosed
EP-3048099-A2 INHIBITORS OF KINASE ACTIVITY YM BioSciences Australia Pty Ltd (AU) 2016-07-27 EP disclosed
US-9029386-B2 Pyridine derivatives useful as kinase inhibitors GILEAD SCIENCES, INC. (US) 2015-05-12 US disclosed
EP-2848610-A1 Inhibitors of kinase activity YM BioSciences Australia Pty Ltd (AU) 2015-03-18 EP disclosed
US-8461161-B2 Substituted pyrazines as inhibitors of kinase activity YM BIOSCIENCES AUSTRALIA PTY LTD (AU) 2013-06-11 US disclosed
US-8461161-B2 Substituted pyrazines as inhibitors of kinase activity YM BIOSCIENCES AUSTRALIA PTY LTD (AU) 2013-06-11 US disclosed
US-20130137660-A1 INHIBITORS OF KINASE ACTIVITY YM BIOSCIENCES AUSTRALIA PTY LTD (AU) 2013-05-30 US disclosed
US-20100130447-A1 INHIBITORS OF KINASE ACTIVITY YM BIOSCIENCES AUSTRALIA PTY LTD (AU) 2010-05-27 US disclosed
US-20100130447-A1 INHIBITORS OF KINASE ACTIVITY YM BIOSCIENCES AUSTRALIA PTY LTD (AU) 2010-05-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130137660-A1 INHIBITORS OF KINASE ACTIVITY FRK, LCK, FLT3 CSF1R 62/4885BRAF 375/4885RAF1 347/4885
US-20100130447-A1 INHIBITORS OF KINASE ACTIVITY FRK, LCK, FLT3 CSF1R 62/4885BRAF 375/4885RAF1 347/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.